Clipping of news on Brazilian Culture, Law and Citizenship
01/02/2015
This article was translated by an automatic translation system, and was therefore not reviewed by people.
transparent image
Paula Laboissière- reporter Agency Brazil Edition: Talita Cavalcante
The discussion on the reclassification of cannabidiol will resume in the first half of this month by the National Sanitary Surveillance Agency (ANVISA), during a meeting of the executive board. Currently, cannabidiol is on the list of prohibited substances (prohibited) in Brazil. Cannabidiol is a substance present in the leaf of marijuana (Cannabis sativa), which is used for the treatment of neurological diseases, cancer, Parkinson's disease, among others.
The director of institutional management Ivo Bucaresky ANVISA, announces seal and notes to power in 2014 World Cup (Wilson Dias / Agency Brazil)
For the substitute president of ANVISA, Ivo Bucaresky, the reclassification will facilitate the import of cannabidiol for legal entities and for scientific research Wilson Dias / File / Agency Brazil......
Learn More
ANVISA simplifies cannabidiol import process by individuals
Anvisa studies reclassify cannabidiol as medicine, says president
In a public hearing in the Committee on Social Security and Family of the House of Representatives in November 2014, replaced the president of Anvisa, Ivo Bucaresky explained the motions. "As a derivative of cannabis, canadibiol was included in List E, which is the list of plants that can cause narcotic drugs and psychotropic substances, and in Listing F, which are susbtâncias of prohibited use in Brazil, narcotics and psychotropic substances". if reclassified, it goes to the "List C1, which is a list of [medicines] controlled that involves a lot of drugs." According to Bucaresky, the reclassification will facilitate the import of the substance for legal entities and for scientific research.
Last year, the agency has simplified the procedures for the import of cannabidiol-based products for individuals and for personal use. With the change, the documentation submitted by the parties is valid for one year, requiring only the medical prescription every new import request.
For the first import, the applicant must fill out a form with general data, submit the prescription and the medical report to ANVISA. The applicant must also sign a liability waiver with the treating physician. If there is a change of prescriber, signing new document will be required.
Also in 2014, the Federal Council of Medicine decided to allow neurosurgeons and psychiatrists to prescribe cannabidiol-based remedies for children and adolescents with epilepsy whose conventional treatments have not been effective.
Source: Agency Brazil
Our news are taken in full of our partner sites. For this reason, we can not change their content even in cases of typos. transparent image
This article was translated by an automatic translation system, and was therefore not reviewed by people.